Cellceutix commits to mid-stage study of Kevetrin in ovarian cancer

• Cellceutix (CTIX -1%) says it is moving forward with a Phase 2 clinical trial assessing Kevetrin for the treatment of late-stage platinum-resistant ovarian cancer. At present, it is administered intravenously but the company will pursue an oral formulation to improve patient convenience and potentially increase efficacy considering the drug's short half-life of ~1 hour. Also, a preliminary toxicity study showed 500 mg/kg administered once daily for seven days produced no safety signals (the dose was greater that that used in the preclinical efficacy study)
• Kevetrin is a small molecule that induces the activation of the tumor suppressor protein p53.
• Previously: Cellceutix bags Rare Pediatric Disease Designation for Kevetrin for type of eye cancer (Dec. 1, 2015)